Q2 2025 EPS Estimates for Ligand Pharmaceuticals Incorporated Lifted by Analyst (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) - Equities researchers at Zacks Research upped their Q2 2025 earnings per share estimates for Ligand Pharmaceuticals in a report released on Tuesday, April 2nd. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings of $1.01 per share for the quarter, up from their previous estimate of $1.00. The consensus estimate for Ligand Pharmaceuticals' current full-year earnings is $3.41 per share. Zacks Research also issued estimates for Ligand Pharmaceuticals' Q3 2025 earnings at $1.00 EPS, FY2025 earnings at $3.98 EPS, Q1 2026 earnings at $1.19 EPS and FY2026 earnings at $4.60 EPS.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.55. The business had revenue of $28.10 million during the quarter, compared to the consensus estimate of $24.54 million. Ligand Pharmaceuticals had a return on equity of 11.98% and a net margin of 37.80%.

LGND has been the subject of a number of other reports. Benchmark restated a "buy" rating and issued a $95.00 target price on shares of Ligand Pharmaceuticals in a research report on Wednesday, December 13th. HC Wainwright reiterated a "buy" rating and set a $144.00 price objective on shares of Ligand Pharmaceuticals in a research report on Thursday, February 29th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $116.33.

Ligand Pharmaceuticals Stock Down 0.0 %

LGND traded down $0.02 during trading on Friday, reaching $77.96. The stock had a trading volume of 165,690 shares, compared to its average volume of 159,363. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of 28.36 and a beta of 1.01. Ligand Pharmaceuticals has a 1-year low of $49.24 and a 1-year high of $94.57. The stock has a 50 day moving average of $74.23 and a two-hundred day moving average of $66.27.

Insider Buying and Selling at Ligand Pharmaceuticals

In other Ligand Pharmaceuticals news, Director Stephen L. Sabba sold 1,893 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $74.30, for a total transaction of $140,649.90. Following the sale, the director now directly owns 28,926 shares of the company's stock, valued at approximately $2,149,201.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 10.40% of the company's stock.

Institutional Trading of Ligand Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Stephens Investment Management Group LLC increased its stake in shares of Ligand Pharmaceuticals by 41.0% in the fourth quarter. Stephens Investment Management Group LLC now owns 659,434 shares of the biotechnology company's stock worth $47,097,000 after acquiring an additional 191,870 shares during the last quarter. Norges Bank acquired a new position in shares of Ligand Pharmaceuticals in the fourth quarter worth $9,690,000. Pacer Advisors Inc. increased its stake in shares of Ligand Pharmaceuticals by 59.1% in the fourth quarter. Pacer Advisors Inc. now owns 325,727 shares of the biotechnology company's stock worth $23,263,000 after acquiring an additional 121,049 shares during the last quarter. BlackRock Inc. increased its stake in shares of Ligand Pharmaceuticals by 2.4% in the second quarter. BlackRock Inc. now owns 2,906,159 shares of the biotechnology company's stock worth $209,534,000 after acquiring an additional 67,497 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Ligand Pharmaceuticals by 132.8% in the fourth quarter. Marshall Wace LLP now owns 92,863 shares of the biotechnology company's stock worth $6,203,000 after acquiring an additional 52,980 shares during the last quarter. 91.28% of the stock is owned by institutional investors and hedge funds.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.